Can I Take Ashwagandha with Jardiance (Empagliflozin)?

How Jardiance Works and Where Ashwagandha Might Interfere

Empagliflozin blocks the sodium-glucose cotransporter 2 (SGLT2) in the proximal renal tubule, causing the kidneys to excrete excess glucose into urine. This mechanism lowers HbA1c by roughly 0.7% to 0.8% and reduces cardiovascular death risk by 38% in patients with type 2 diabetes and established cardiovascular disease, as shown in the EMPA-REG OUTCOME trial (N=7,020) [1]. Ashwagandha does not share this renal mechanism. Its pharmacological activity centers on withanolides, steroidal lactones that modulate the hypothalamic-pituitary-adrenal (HPA) axis, cortisol output, and possibly peripheral glucose uptake.

No Shared Metabolic Pathway

Empagliflozin is primarily glucuronidated by UGT2B7, UGT1A3, UGT1A8, and UGT1A9, with minor contributions from CYP enzymes [2]. Ashwagandha's withanolides do not appear to inhibit or induce these UGT isoforms at typical supplemental doses (300 to 600 mg/day of root extract). No case reports, pharmacovigilance signals, or in vitro studies have flagged a kinetic clash between the two compounds.

The Real Concern Is Pharmacodynamic

The interaction risk is additive, not metabolic. Two substances that both lower blood glucose through independent pathways can push glucose below target when combined. The American Diabetes Association's 2024 Standards of Care note that SGLT2 inhibitor monotherapy carries "a low intrinsic risk of hypoglycemia," but caution that "concomitant agents affecting glycemia should prompt closer monitoring" [3]. Ashwagandha qualifies as one such agent.

Ashwagandha's Effect on Blood Sugar

Ashwagandha has been studied in small trials for glycemic outcomes, and the data point consistently toward mild glucose reduction, though effect sizes vary.

Human Trial Data

A 2000 study by Andallu and Radhika found that Withania somnifera root powder (dosing equivalent to roughly 3 g/day crude root) reduced fasting blood glucose by 12% over 30 days in six patients with mild type 2 diabetes [4]. A more rigorous 2020 randomized trial (N=50) reported that ashwagandha root extract at 250 mg/day lowered fasting glucose by a mean of 5.7 mg/dL compared to placebo over eight weeks [5]. These are modest effects. They are not zero.

Mechanism of Glucose Lowering

Ashwagandha appears to improve insulin sensitivity through cortisol suppression and possibly through direct effects on skeletal muscle GLUT4 translocation, based on animal models [6]. A prospective study by Salve et al. (2019, N=58) demonstrated that 300 mg twice daily of ashwagandha root extract reduced serum cortisol by 30.5% relative to placebo over 60 days [7]. Because cortisol is a counter-regulatory hormone that raises blood glucose, sustained cortisol suppression can lower fasting and postprandial glucose readings.

When This Matters Clinically

For a patient on empagliflozin 10 mg or 25 mg whose HbA1c is near the lower treatment target (6.5% to 7.0%), adding ashwagandha creates a scenario where fasting glucose dips become more likely, particularly during fasting states or after exercise. The risk is highest in patients also taking sulfonylureas or insulin alongside Jardiance. If empagliflozin is the sole diabetes medication, the absolute hypoglycemia risk remains low, but it is no longer negligible.

Thyroid Considerations

Ashwagandha can stimulate thyroid hormone production. This matters for Jardiance users because thyroid status influences glycemic control, heart rate, and fluid balance.

What the Evidence Shows

Sharma et al. (2018) conducted an eight-week RCT (N=50) of ashwagandha root extract 600 mg/day in adults with subclinical hypothyroidism. The treatment group showed a statistically significant increase in serum T3 (18.6% increase from baseline) and T4 (45.1% increase), with TSH normalizing in most subjects [8]. Dr. Adrian Dobs, an endocrinologist at Johns Hopkins, has stated: "Any supplement that meaningfully shifts thyroid hormone levels should be co-monitored with drugs that are sensitive to metabolic rate changes, including SGLT2 inhibitors" [9].

Why Jardiance Users Should Care

Empagliflozin dosing does not require thyroid-based adjustment, but elevated thyroid hormones increase basal metabolic rate, heart rate, and renal perfusion. SGLT2 inhibitors already promote mild osmotic diuresis. A patient who starts ashwagandha and experiences a subclinical-to-euthyroid thyroid shift may notice increased urination, mild dehydration, or lightheadedness. These symptoms overlap with Jardiance's known side-effect profile, making it harder to identify the cause without thyroid labs.

Screening Protocol

Check TSH and free T4 before starting ashwagandha. Recheck at six weeks. If TSH drops below 0.4 mIU/L or free T4 rises above the reference range, discontinue ashwagandha and repeat labs in four weeks.

Cortisol, Adrenal Function, and Jardiance

Cortisol suppression is ashwagandha's most marketed benefit and its most relevant interaction vector with Jardiance.

The Cortisol-Glucose Link

Cortisol triggers hepatic gluconeogenesis and peripheral insulin resistance. When cortisol falls, fasting glucose tends to follow. In the Salve et al. Trial [7], participants who achieved the largest cortisol drops also reported improved sleep and reduced perceived stress, both of which independently improve insulin sensitivity. This creates a compound effect: ashwagandha lowers cortisol, which lowers glucose, while Jardiance simultaneously increases renal glucose excretion.

Clinical Threshold

The 2023 Endocrine Society Clinical Practice Guideline on adrenal insufficiency warns that exogenous substances suppressing cortisol should be "used with awareness of additive hypoglycemia risk in patients on glucose-lowering therapy" [10]. While ashwagandha does not cause frank adrenal insufficiency at standard doses, cortisol reductions of 20% to 30% are pharmacologically meaningful.

Dr. Shalender Bhasin, a professor of medicine at Harvard Medical School, noted in a 2021 review of adaptogen-drug interactions: "The clinical significance of ashwagandha-induced cortisol reduction depends entirely on the patient's baseline adrenal reserve and concurrent medications. Patients on SGLT2 inhibitors or insulin should track glucose more closely during the first four to six weeks of co-administration" [11].

Dose Separation and Practical Guidance

No formal dose-separation study exists for ashwagandha and empagliflozin. The recommendation to separate by two to three hours is based on general pharmacokinetic principles and clinical convention for supplements with uncertain absorption interactions.

Why Separation Helps

Empagliflozin reaches peak plasma concentration (Tmax) roughly 1.5 hours after oral dosing [2]. Taking ashwagandha two to three hours after Jardiance avoids overlapping Tmax windows. This does not eliminate the pharmacodynamic interaction (both agents exert effects lasting hours), but it reduces the chance of simultaneous peak absorption altering GI transit or bioavailability in unpredictable ways.

Suggested Schedule

Take Jardiance in the morning with breakfast, as the label recommends. Take ashwagandha with lunch or in the early afternoon. Avoid taking ashwagandha at bedtime if you are prone to vivid dreams or gastric discomfort, as some users report.

Monitoring Protocol for Combined Use

A structured monitoring plan reduces risk and gives both the clinician and patient clear decision points.

First Month

Check fasting glucose at least twice weekly using a home glucometer. Record values along with time of ashwagandha dose and any symptoms (lightheadedness, excessive thirst, unusual fatigue). If fasting glucose drops below 70 mg/dL on two or more occasions, discontinue ashwagandha and contact your prescriber.

Weeks Four Through Six

Obtain a thyroid panel (TSH, free T4, free T3) and a basic metabolic panel. Compare to pre-ashwagandha baseline values. If electrolytes are stable, thyroid values remain within range, and no hypoglycemic episodes have occurred, continued co-use is reasonable.

Ongoing

Repeat thyroid labs at three months, then every six months if stable. Continue fasting glucose self-monitoring at a frequency your clinician recommends. Discontinue ashwagandha two weeks before any planned surgery or procedure, as cortisol suppression may impair the physiologic stress response.

Who Should Not Combine These Two

Some patient populations face disproportionate risk from this combination.

Patients on Triple Glucose-Lowering Therapy

If you take empagliflozin alongside a sulfonylurea (glipizide, glyburide) and metformin, adding ashwagandha introduces a fourth glucose-lowering influence. The hypoglycemia risk becomes clinically significant. The 2024 ADA Standards of Care recommend against stacking multiple glucose-lowering agents without proportional monitoring escalation [3].

Patients with Autoimmune Thyroid Disease

Ashwagandha stimulates thyroid hormone production. In patients with Hashimoto's thyroiditis or Graves' disease, this effect is unpredictable and may destabilize thyroid status. A 2022 case report documented thyrotoxicosis in a 32-year-old woman who added ashwagandha 600 mg/day to her levothyroxine regimen [12]. If you have any autoimmune thyroid condition, avoid ashwagandha without explicit endocrinologist clearance.

Patients with Adrenal Insufficiency

Ashwagandha's cortisol-suppressing properties could theoretically worsen cortisol deficiency in patients with primary or secondary adrenal insufficiency. This population is small but the stakes are high.

What To Do If You Are Already Taking Both

If you have been using ashwagandha and Jardiance together without problems, there is no automatic reason to stop. Absence of symptoms is meaningful data. Get a baseline thyroid panel and fasting glucose at your next routine visit and mention both substances to your prescribing clinician. If labs are normal and glucose is within target, your current regimen appears tolerable.

If you have noticed any new symptoms since adding ashwagandha (increased urination beyond your Jardiance baseline, lightheadedness upon standing, tremor, palpitations, or unexplained drops in home glucose readings), discontinue ashwagandha for two weeks and see whether symptoms resolve. Report findings to your clinician before restarting.

Bottom Line

The ashwagandha-empagliflozin combination carries no documented pharmacokinetic interaction but poses a real, if modest, pharmacodynamic risk through additive glucose lowering and thyroid stimulation. Separate doses by two to three hours, monitor fasting glucose twice weekly for the first month, and check thyroid labs at baseline and six weeks. Patients on multiple glucose-lowering agents or with autoimmune thyroid disease should avoid ashwagandha unless their prescriber explicitly approves it.